Chen Guann-Yiing, Cheng Jason Chia-Hsien, Chen Ya-Fang, Yang James Chih-Hsin, Hsu Feng-Ming
Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, Taipei 100, Taiwan.
Department of Medical Imaging, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu 300, Taiwan.
Cancers (Basel). 2021 Jan 20;13(3):380. doi: 10.3390/cancers13030380.
Brain metastasis (BM) is a major problem in patients with cancer. Exosomes or extracellular vesicles (EV) and integrins contribute to the development of BM, and exosomal integrins have been shown to determine organotropic metastasis. We hypothesized that circulating EV integrins are able to influence the failure patterns and outcomes in patients treated for BM. We prospectively enrolled 75 lung cancer patients with BM who received whole brain radiotherapy (WBRT). We isolated and quantified their circulating EV integrins, and analyzed the association of EV integrins with clinical factors, survival, and intracranial/extracranial failure. Circulating EV integrin levels were independent of age, sex, histology, number of BM, or graded prognostic assessment score. Age, histology, and graded prognostic assessment score correlated with survival. Patients with higher levels of circulating EV integrin β3 had worse overall survival (hazard ratio: 1.15 per 1 ng/mL increase; = 0.04) following WBRT. Multivariate regression analysis also showed a higher cumulative incidence of intracranial failure (subdistribution hazard ratio: 1.216 per 1 ng/mL increase; = 0.037). In conclusion, circulating EV integrin β3 levels correlated with survival and intracranial control of patients with lung cancer after WBRT for BM. This supports that EV integrin β3 mediates a brain-tropic metastasis pattern, and may serve as a novel prognostic biomarker for BM.
脑转移(BM)是癌症患者面临的一个主要问题。外泌体或细胞外囊泡(EV)以及整合素在BM的发展过程中发挥作用,并且已证实外泌体整合素可决定器官特异性转移。我们推测循环中的EV整合素能够影响接受BM治疗患者的失败模式和预后。我们前瞻性地纳入了75例接受全脑放疗(WBRT)的肺癌脑转移患者。我们分离并定量了他们循环中的EV整合素,并分析了EV整合素与临床因素、生存率以及颅内/颅外失败之间的关联。循环中的EV整合素水平与年龄、性别、组织学类型、BM数量或分级预后评估评分无关。年龄、组织学类型和分级预后评估评分与生存率相关。接受WBRT后,循环中EV整合素β3水平较高的患者总生存期较差(风险比:每增加1 ng/mL为1.15;P = 0.04)。多变量回归分析还显示颅内失败的累积发生率较高(亚分布风险比:每增加1 ng/mL为1.216;P = 0.037)。总之,循环中的EV整合素β3水平与肺癌患者接受WBRT治疗BM后的生存率和颅内控制相关。这支持了EV整合素β3介导脑特异性转移模式,并可能作为BM的一种新型预后生物标志物。